Navidea signs option to license PD imaging agent

Navidea Biopharmaceuticals (AMEX:NAVB), formerly Neoprobe,  has entered into a six-month option agreement with Alseres Pharmaceuticals to license [123I]-E-IAFCT Injection, also called Altropane, an Iodine-123 radio-labeled imaging agent, being developed as an aid in the diagnosis of Parkinson’s disease and movement disorders. “Should we exercise the option, [123I]-E-IAFCT would provide us not only with another strong [...]

Cynapsus readies first human data of sublingual strip for PD

Cynapsus Therapeutics (TSX-V:CTH) is set to release human proof-of-concept data of its sublingual thin film-strip as a treatment for motor fluctuations, or episodes of immobility, in patients with Parkinson’s disease. “This will represent an important de-risking event for the project,” CEO Anthony Giovinazzo says in an exclusive interview with BioTuesdays.com, referring to the company’s APL-130277 [...]

Cynapsus arranges debenture financing

Cynapsus Therapeutics (TSX-V:CTH) has arranged a financing of $229,885 of 10% of secured Series E-4 debentures due Dec. 30, 2012. As part of the financing, the company will pay a 13% capital discount to the debenture holders, resulting in net proceeds to Cynapsus of $200,000 and issue 800,000 common shares to the debenture holders at [...]

Cynapsus closes Adagio acquisition

Cynapsus Therapeutics (TSX-V:CTH) has completed the acquisition of Adagio Pharmaceuticals in a share exchange, terminating a license option agreement for the intellectual property owned by Adagio concerning the APL-130277 patent rights and know-how. “Cynapsus is focused on advancing our Parkinson’s drug candidate, APL-130277, and the original patent rights and know how held by Adagio are [...]

Amorfix turnaround builds broad pipeline

What a difference a year makes. In 2010, Amorfix Life Sciences (TSX:AMF) pulled the plug on its lead blood test to detect the human variant of Creutzfeldt-Jakob disease, thereby halving its stock price and prompting a management shakeup. Today, Amorfix has built an innovative, early-stage product pipeline, including diagnostics and therapeutics for neurodegenerative diseases and [...]

Ceregene reports new findings in Parkinson’s

Scientists and collaborators of closely held Ceregene have published new experimental findings in support of its Parkinson’s disease program which appeared as the lead article in the current issue of Movement Disorders. The publication reports the first evidence that gene transfer can provide targeted expression of a neurotrophic factor, neurturin or NRTN, intended to restore [...]

Cynapsus licenses in Parkinson’s drug

Cynapsus Therapeutics (TSX-V:CTH) has signed a license option agreement for all intellectual property  related to Adagio Pharmaceuticals’ APL-130277, a reformulation of an approved Parkinson’s drug. Under the accord, Adagio is entitled to receive 750,000 common shares of Cynapsus based on a price of 10 cents a share. A 12-month exclusive option period allows Cannasat to [...]

Biovail in license pact with Kyowa Hakko Kirin

Biovail (NYSE:BVF; TSX:BVF) has entered into a license agreement with Japan’s  to acquire the U.S. and Canadian rights to commercialize products containing istradefylline A, a new chemical entity targeted for the treatment of Parkinson’s disease. Under the accord, Biovail paid an upfront fee of $10 million, and could pay up to $20 million in potential [...]

In conversation with Dr. Erich Mohr

Dr. Erich Mohr enjoyed his time in academia as a neuropsychologist at the U.S. National Institutes of Health and University of Ottawa.  But he couldn’t resist the entrepreneurial call when it came knocking in 1996. Teaming up with a good friend, they formed CroMedia Global, a contract research organization that grew to 550 employees in [...]